Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51 results about "Lysyl oxidase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lysyl oxidase (LOX), also known as protein-lysine 6-oxidase, is an enzyme that, in humans, is encoded by the LOX gene. It catalyzes the conversion of lysine molecules into highly reactive aldehydes that form cross-links in extracellular matrix proteins. Its inhibition can cause osteolathyrism, but, at the same time, its upregulation by tumor cells may promote metastasis of the existing tumor, causing it to become malignant and cancerous.
Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
InactiveUS20070021365A1Good curative effectInhibit biological activityCompound screeningApoptosis detectionAbnormal tissue growthCancer research
Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method and composition for treating and preventing tumor metastasis in vivo
InactiveUS20070225242A1Increasing and enhancing chance of survivalIncreasing or enhancing the chances of survival of the subject treatedOrganic active ingredientsCompound screeningAbnormal tissue growthLymphatic Spread
Methods, compositions and kits are provided for effectively treating and preventing cancer metastasis in vivo and for increasing survival of subjects burdened with metastatic tumors by targeting a lysyl oxidase or its modulator, especially human lysyl oxidase. Also provided are methods for identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Stimulation of the activity of an isoform of lysyl oxidase for combating against some pathologies due to an incomplete, absent or disorganized elastogenesis
The invention relates to the stimulation of the activity of an isoform of lysyl oxidase, and more particularly of the LOX (lysyl oxidase) isoform. The invention relates notably to a screening method of an active principle which regulates elastogenesis in cases of pathological, disorganized and / or non-functional elastogenesis, as in cases of fibrosis, of solar elastosis, of stretch marks, and / or of dystrophic scars; and / or in cases of some eczematous pathologies. The aim of the invention is mainly to provide such a screening method so as to provide compositions enabling the elastogenesis in the cases cited to be regulated.
Owner:CENT NAT DE LA RECHERCHE SCI +1
Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
InactiveUS20060134172A1Lower eye pressureInhibit expressionSenses disorderEye treatmentProteinase activityNucleotide
The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).
Owner:ALCON INC
Chemotherapeutic methods and compositions
ActiveUS20100209415A1Enhance cell killing activityEnhance killing activityOrganic active ingredientsHeavy metal active ingredientsCell-Extracellular MatrixECM Protein
Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.
Owner:GILEAD BIOLOGICS
Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers.
InactiveUS20100040710A1Increase elasticityCut skinCosmetic preparationsCompound screeningFiberBiology
Owner:BASF BEAUTY CARE SOLUTIONS FRANCE SAS
Use of the Pro-Peptide Domain of Lysyl Oxidase as a Therapeutic Agent
A therapeutic composition that includes an active portion of the lysyl oxidase pro-peptide in a pharmaceutically acceptable carrier substance and methods of using such a therapeutic composition are disclosed. The active agent does not have lysyl oxidase enzymatic activity. Preferably, the active polypeptide is active in inhibiting cell growth in soft agar and active in inhibiting tumor formation. In addition, the active polypeptide preferably comprises an active portion of the amino acid sequence given in SEQ ID NO.: 1 or SEQ ID NO.: 2, or conservative substitions thereof. Alternatively, the active polypeptide comprises a polypeptide comprising an active portion of an amino acid sequence selected from the group consisting of SEQ ID NOs.: 3-8, or conservative substitions thereof.
Owner:TRACKMAN PHILIP C +3
Chemotherapeutic methods and compositions
ActiveUS20130017207A1High activityEnhance killing activityOrganic active ingredientsHeavy metal active ingredientsCell-Extracellular MatrixECM Protein
Owner:GILEAD BIOLOGICS
Synthesis of human procollagens and collagens in recombinant DNA systems
InactiveUS20050164345A1Quality improvementImprove purification effectConnective tissue peptidesBacteriaLysyl hydroxylaseRecombinant DNA
Methods of making collagen with hosts, and vectors that express collagen, and collagen post-translation enzymes are disclosed. Collagen post-translation enzymes include prolyl-4-hydroxylase, lysyl hydroxylase, lysyl oxidase, C-proteinase, and N-proteinase, and these enzymes increase the yield of properly folded, recombinant collagen in non-mammalian hosts. The collagens produced by these methods, hosts, and vectors include both homotrimer and heterotrimer collagen made from single or multiple collagen genes, respectively.
Owner:KIVIRIKKO KARI +1
Novel human-like collagen haemostatic dressing
ActiveCN105536043AGood biocompatibilityGrowth promotionPharmaceutical delivery mechanismBandagesChelated calciumFreeze-drying
The invention discloses a novel human-like collagen haemostatic dressing which has good biocompatibility, can be absorbed and is rich in calcium, zinc, copper and iron, and discloses a preparation method of the novel human-like collagen haemostatic dressing. The preparation method comprises the following steps: by taking modified protein obtained by chelating humanized human-like collagen prepared by high-density fermentation with calcium, zinc, copper and iron ions respectively as a raw material as well as taking lysyloxidase existing in mammals as a cross-linking agent, carrying out low-temperature cross-linking reaction and freeze-drying processes to obtain the novel collagen haemostatic dressing which can be used for hemostasis of wounds and postoperative hemostasis. The preparation method disclosed by the invention has the advantages that the raw materials are easy to obtain, the cost is low, the synthetic process is simple and easy to realize, process amplification is easy, and the reproducibility is good; and the human-like collagen haemostatic dressing prepared by the preparation method does not have animal-derived virus hidden danger, has an obvious haemostatic effect, can be used for hemostasis of various wounds and postoperative hemostasis, and can be used for basic research and application of related fields, such as biomedical tissue engineering.
Owner:NORTHWEST UNIV(CN)
Antibacterial human-like collagen wound care film dressing
The invention discloses novel antibacterial human-like collagen wound care film dressing which has good biocompatibility, is absorbable and is enriched with calcium, zinc, copper and silver elements as well as a preparation method of the film dressing. According to the preparation method, modified protein obtained by chelating calcium, zinc and copper ions on human-derived human-like collagen prepared through high-density fermentation is taken as a raw material, lysyl oxidase in a mammal body is taken as a cross-linking agent, and the novel antibacterial human-like collagen wound care film dressing which can be used for burn scald and skin wound is obtained through supporting of free silver ions due to the high absorption characteristic in the low-temperature crosslinking reaction and freeze drying process. Hidden danger caused by animal-derived viruses is avoided, and the hemostatic effect is remarkable; the contained silver ions can prevent the wound from being invaded by bacteria. The care dressing can be used for treating various wounds and has a wide application prospect.
Owner:NORTHWEST UNIV
Polymorphisms in elastin, fibrillin and related genes as predisposing to restenosis and to a therosclerosis
InactiveUS20050282163A1Rapidly and objectively predictEfficaciousMicrobiological testing/measurementGenetic material ingredientsPercent Diameter StenosisBiglycan
Methods are provided for assessing the risk of developing restenosis in an individual, by detecting the presence of biologically important polymorphisms in genes involved in the formation of the elastin fiber network. In particular, detection of polymorphorphisms in the elastin, fibrillin, fibrillin-1, fibrillin-2, lysyl oxidase, microfibril-associated glycoprotein, biglycan, osteopontin, and / or decorin genes allows the rapid and objective prediction of the risk of developing restenosis. Methods for treating restenosis and for reducing its recurrence also are provided.
Owner:MEDSTAR RES INST
Kit for detecting susceptibility gene of glaucoma
The invention discloses a kit for detecting a susceptibility gene of glaucoma. The kit comprises specific primer pairs, specific fluorescent probe pairs, conventional components and the like, wherein the specific primer pairs and the specific fluorescent probe pairs are used for simultaneously detecting a No.rs3825942 SNP (single nucleotide polymorphism) site on an LOXL (lysyl oxidase-like)1 gene and a No.rs4236601 SNP site on a CAV (chicken anemia virus)1 / CAV2 gene; the conventional components are used for fluorescent quantitative PCR (polymerase chain reaction) detection. The kit is used for evaluating the risk of suffering from glaucoma by individuals by simultaneously detecting SNP site genotypes of LOXL1 and CAV1 / CAV2 closely related to glaucoma.
Owner:浙江爱易生物医学科技有限公司
Methods and Drug Therapies for Patency of Occluded Blood Vessels Following Angioplasty
The present disclosure relates to a method of maintaining luminal patency of a blood vessel following vessel injury, the method including administering a composition comprising at least one lysyl oxidase inhibitor and D-penicillamine to a subject in need thereof Compositions to support the methods are also provided.
Owner:NEPHROGENESIS
Fungus-origin lysyl oxidases
Owner:AMANO ENZYME INC
Antibodies targeted against loxl-2 for the treatment of collagen-associated pathologies
ActiveUS20170210823A1Heavy metal active ingredientsAntibody ingredientsCell-Extracellular MatrixAnticarcinogen
An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and / or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.
Owner:YEDA RES & DEV CO LTD
Chemotherapeutic methods and compositions
ActiveUS9107935B2High activityEnhance killing activityHeavy metal active ingredientsGenetic material ingredientsCell-Extracellular MatrixECM Protein
Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.
Owner:GILEAD BIOLOGICS
Compound lozenge controlling childe tooth decay
InactiveCN105169375AEvenly dispersedHigh encapsulation efficiencyAntibacterial agentsHydroxy compound active ingredientsSolventAnaphylactic reaction
The invention discloses a compound lozenge controlling childe tooth decay, and belongs to the technical field of medicines. The lozenge comprises medicinal compositions and auxiliary material compositions. The medicinal compositions comprise, in parts by weight, 1-3 parts of lysyl oxidase, 1.5-2.5 parts of D-galactose, 5-8 parts of nanometer diatomite, 0.2-0.6 part of calcium dihydrogen phosphate, 0.11-0.13 part of chromium picolinate, 0.08-0.1 part of tretinoin, 0.02-0.03 part of tiamcinolone acetonide. The auxiliary material compositions comprise, in parts by weight, 70-100 parts of a medicine carrier, 0.12-0.25 part of a solvent, 0.01-0.03 part of an aseptic, 0.14-0.26 part of compound vitamin, and 2-5 parts of a corrigent. The lozenge contains multiple effective compositions, is reasonable in matching ratio, is capable of resisting bacteria, diminishing inflammation, removing dental plaque and harmful bacteria, preventing and treating decayed teeth and preventing carious teeth, does not cause anaphylactic reaction, and enhances oral cavity health-care effect.
Owner:吕欢
Wound healing compositions and methods using tropoelastin and lysyl oxidase
InactiveUS20050175600A1Improve the environmentPromote healingPeptide/protein ingredientsOxidoreductasesDamages tissueElastin tissue
The present invention provides compositions and methods for promoting wound healing. The composition comprises virgin monomers of tropoelastin and lysyl oxidase. When the lysyl oxidase comes in contact with the tropoelastin, cross-linking of the tropoelastin monomers will occur to form elastin. Contacting the tropoelastin and lysyl oxidase together and applying the mixture to a wound before substantial cross-linking has occurred promotes wound healing by holding the damaged tissue together, increasing the rate of healing, and decreasing the amount of scarring.
Owner:MATRIX DESIGN
Wound healing compositions and methods using tropoelastin and lysyl oxidase
InactiveUS20080038243A1Improve the environmentPromote healingPeptide/protein ingredientsDepsipeptidesDamages tissueElastin tissue
Owner:MATRIX DESIGN
Topical skin compositions for treating rosacea and skin redness
ActiveUS20200261531A1Reduce skin inflammationIncreased agonist activityCosmetic preparationsBacteria material medical ingredientsPimpleVascular dilatation
The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of Phoenix dactylifera extract, tea tree oil, Myrothamnus flabellifolia extract, and saccharide isomerate. This combination can be used to create topical skin compositions that reduce rosacea, erythema, and / or inflammation, and inhibit nitric oxide synthase, increase α2A adrenergic receptor agonist activity, reduce oxidation, increase anti-oxidant capacity of a composition or of skin, inhibit cyclooxygenase-2 (COX-2) production, inhibit vascular endothelial growth factor (VEGF) production, inhibit interleukin-6 (IL-6) and interleukin-8 (IL-8) production, reduce tumor necrosis factor alpha (TNF-α) production, increase collagen stimulation, increase lysyl oxidase expression, inhibit matrix metalloproteinase 1 (MMP1) activity, increase occludin production, increase filaggrin production, and increase skin moisturization. This combination can also be used to reduce transient or persistent erythema, telangiectasia, inflammatory papules and / or pustules, transient or persistent flushing of the skin, and / or hyperplasia of a connective tissue.
Owner:MARY KAY INC
A cross-linking treatment method for improving the stability of biological valve elastin
Owner:VENUS MEDTECH (HANGZHOU) INC
DNA markers for meat tenderness
InactiveUS7625698B2Reduce the impactSugar derivativesMicrobiological testing/measurementAlleleMeat tenderness
A method for assessing the tenderness of meat from an animal, comprising the step of testing the animal for the presence or absence of a genetic marker selected from the group consisting of:(1) an allele of the gene encoding calpastatin (CAST) associated with peak-force variation or genetic variation located other than in the CAST gene which shows allelic association with the CAST allele; and(2) an allele of the gene encoding lysyl oxidase (LOX) associated with instron compression of the semitendinosis muscle or genetic variation located other than in the LOX gene which shows allelic association with the LOX allele.
Owner:COMMONWEALTH SCI & IND RES ORG +4
Topical skin compositions for treating rosacea and skin redness
ActiveUS11090352B2Reduce skin inflammationReduced activityCosmetic preparationsBacteria material medical ingredientsPimpleVascular dilatation
Owner:MARY KAY INC
Combined Biomarker Measurements of Fibrosis
Owner:NORDIC BIOSCI
Lox inhibitors
The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.
Owner:THE INST OF CANCER RES ROYAL CANCER HOSPITAL
Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and / or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
Owner:PHARMAXIS LTD
Medium for culturing hematopoietic cells and a method of culturing hematopoietic cells
InactiveUS20090117654A1Efficiently proliferatedPeptide/protein ingredientsCulture processHematopoietic cellMicrobiology
Provided are a medium for culturing hematopoietic cells including lysyl oxidase inhibitor and a method of culturing hematopoietic cells using the medium.
Owner:SAMSUNG ELECTRONICS CO LTD
Matrix bound vesicles (MBVS) containing il-33 and their use
Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation.
Owner:联邦高等教育系统匹兹堡大学
Antibodies targeted against LOXL-2 for the treatment of collagen-associated pathologies
ActiveUS10040868B2Heavy metal active ingredientsAntibody ingredientsCell-Extracellular MatrixAnticarcinogen
Owner:YEDA RES & DEV CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com